James J Driscoll

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy
    James J Driscoll
    Translational Genomics Section, Medical Oncology Branch, National Cancer Institute, Magnuson Cancer Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Ther 19:133-44. 2012
  2. ncbi The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
    James J Driscoll
    Department of Research, Veterans Administration Boston Healthcare, West Roxbury, MA, USA
    Blood 115:2827-34. 2010
  3. ncbi Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy
    James J Driscoll
    Medical Oncology Branch, Magnuson Cancer Center, National Cancer Institute, National Institutes of Health, 10 Center Drive Building 10, Room 12N 226, Bethesda, MD 20892, USA
    Target Oncol 5:281-9. 2010
  4. ncbi The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies
    James J Driscoll
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Anticancer Agents Med Chem 11:242-6. 2011
  5. ncbi Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials
    James J Driscoll
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer J 15:401-5. 2009

Detail Information

Publications5

  1. ncbi Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy
    James J Driscoll
    Translational Genomics Section, Medical Oncology Branch, National Cancer Institute, Magnuson Cancer Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Ther 19:133-44. 2012
    ..Herein, the use of bortezomib as an upfront therapy, as an induction regimen before stem-cell transplantation and as maintenance therapy in the treatment of multiple myeloma is discussed...
  2. ncbi The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
    James J Driscoll
    Department of Research, Veterans Administration Boston Healthcare, West Roxbury, MA, USA
    Blood 115:2827-34. 2010
    ..The sumoylation pathway is a novel therapeutic target with implications for existing proteasomal-based treatment strategies...
  3. ncbi Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy
    James J Driscoll
    Medical Oncology Branch, Magnuson Cancer Center, National Cancer Institute, National Institutes of Health, 10 Center Drive Building 10, Room 12N 226, Bethesda, MD 20892, USA
    Target Oncol 5:281-9. 2010
    ..Targeting the UPS, SUMOylation and NEDDylation pathways offers great promise in the treatment of hematologic and solid malignancies...
  4. ncbi The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies
    James J Driscoll
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Anticancer Agents Med Chem 11:242-6. 2011
    ..Potential mechanisms of resistance and means to improve the response to proteasome inhibitors in solid tumors are discussed...
  5. ncbi Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials
    James J Driscoll
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer J 15:401-5. 2009
    ..Clinical trials must continue to assess OS until biologically plausible measures are developed and emerge as valid early end point surrogates to replace the gold standard...